See more : ADM Energy plc (ADME.L) Income Statement Analysis – Financial Results
Complete financial analysis of Simulations Plus, Inc. (SLP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Simulations Plus, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Fullcast Holdings Co., Ltd. (4848.T) Income Statement Analysis – Financial Results
- KOREA NO.15 SPECIAL PURPOSE ACQUISITION CO., LTD. (479880.KQ) Income Statement Analysis – Financial Results
- Blue Star Foods Corp. (BSFC) Income Statement Analysis – Financial Results
- Zalaris ASA (ZAL.OL) Income Statement Analysis – Financial Results
- Cross Plus Inc. (3320.T) Income Statement Analysis – Financial Results
Simulations Plus, Inc. (SLP)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.simulations-plus.com
About Simulations Plus, Inc.
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.01M | 59.58M | 53.91M | 46.47M | 41.59M | 33.97M | 29.67M | 24.14M | 19.97M | 18.31M | 11.46M | 10.07M | 9.45M | 11.72M | 10.71M | 9.14M | 8.97M | 8.86M | 5.86M | 4.75M | 5.21M | 5.48M | 4.44M | 3.91M | 3.63M | 3.47M | 2.65M | 2.49M | 2.60M |
| Cost of Revenue | 26.86M | 11.63M | 10.82M | 10.60M | 10.65M | 9.03M | 7.99M | 6.31M | 4.60M | 4.32M | 1.63M | 1.65M | 1.51M | 2.88M | 2.55M | 2.32M | 2.10M | 2.08M | 1.60M | 1.51M | 1.56M | 1.54M | 1.46M | 1.56M | 1.16M | 1.65M | 1.76M | 1.25M | 1.20M |
| Gross Profit | 43.15M | 47.95M | 43.08M | 35.87M | 30.94M | 24.94M | 21.67M | 17.83M | 15.37M | 14.00M | 9.83M | 8.42M | 7.94M | 8.84M | 8.17M | 6.82M | 6.87M | 6.78M | 4.25M | 3.24M | 3.65M | 3.95M | 2.99M | 2.35M | 2.47M | 1.82M | 889.25K | 1.24M | 1.40M |
| Gross Profit Ratio | 61.63% | 80.48% | 79.92% | 77.19% | 74.39% | 73.43% | 73.05% | 73.87% | 76.96% | 76.43% | 85.79% | 83.65% | 84.02% | 75.44% | 76.23% | 74.61% | 76.58% | 76.49% | 72.60% | 68.27% | 70.09% | 71.96% | 67.23% | 60.08% | 67.98% | 52.45% | 33.62% | 49.77% | 53.85% |
| Research & Development | 5.75M | 4.50M | 3.21M | 4.05M | 2.97M | 2.50M | 1.79M | 1.37M | 1.45M | 1.33M | 952.77K | 802.37K | 947.56K | 935.20K | 969.87K | 1.11M | 990.49K | 814.95K | 445.25K | 524.56K | 515.02K | 379.63K | 382.14K | 354.09K | 299.88K | 218.51K | 390.45K | 133.02K | 100.00K |
| General & Administrative | 22.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.56M | 6.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 8.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 131.78K | 38.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 31.27M | 34.72M | 24.97M | 20.57M | 16.36M | 11.80M | 9.58M | 8.20M | 6.69M | 6.81M | 4.44M | 3.55M | 3.38M | 4.31M | 4.33M | 3.90M | 3.70M | 3.46M | 2.97M | 2.42M | 2.51M | 2.30M | 2.11M | 2.20M | 2.14M | 2.31M | 2.68M | 2.28M | 1.20M |
| Other Expenses | 0.00 | 2.97M | 204.00K | 0.00 | 14.30B | 14.30B | 8.14B | 0.00 | 0.00 | 0.00 | 0.00 | 35.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 261.15K | 0.00 | 0.00 | 0.00 | 100.00K |
| Operating Expenses | 37.02M | 39.22M | 28.17M | 24.61M | 19.33M | 14.30M | 11.37M | 9.57M | 8.14M | 8.14M | 5.39M | 4.35M | 4.33M | 5.24M | 5.30M | 5.01M | 4.69M | 4.27M | 3.42M | 2.95M | 3.02M | 2.68M | 2.49M | 2.55M | 2.70M | 2.53M | 3.07M | 2.41M | 1.40M |
| Cost & Expenses | 63.88M | 50.85M | 39.00M | 35.21M | 29.98M | 23.32M | 19.37M | 15.87M | 12.74M | 12.46M | 7.02M | 6.00M | 5.84M | 8.12M | 7.84M | 7.33M | 6.79M | 6.36M | 5.02M | 4.46M | 4.58M | 4.22M | 3.94M | 4.12M | 3.87M | 4.18M | 4.83M | 3.66M | 2.60M |
| Interest Income | 4.38M | 4.13M | 717.00K | 201.00K | 29.47K | 33.52K | 27.12K | 15.86K | 18.01K | 17.94K | 31.44K | 49.49K | 89.27K | 91.86K | 101.55K | 93.87K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 233.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 717.00K | 22.00K | 0.00 | 109.08K | 153.03K | 38.19K | 18.01K | 17.94K | 31.44K | 49.49K | 3.00 | 118.00 | 1.05K | 93.87K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.36K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.67M | 3.84M | 3.57M | 3.59M | 2.96M | 2.75M | 2.72M | 2.14M | 1.93M | 1.99M | 1.04M | 766.96K | 715.44K | 747.30K | 682.94K | 561.01K | 543.42K | 512.45K | 363.18K | 206.89K | 223.98K | 195.60K | 191.83K | 293.85K | 261.15K | 503.76K | 632.09K | 139.86K | -100.00K |
| EBITDA | 11.80M | 12.57M | 18.49M | 14.70M | 11.85M | 13.31M | 11.72M | 10.38M | 9.17M | 7.68M | 5.48M | 4.84M | 4.67M | 4.52M | 3.79M | 2.59M | 2.72M | 3.02M | 1.20M | 503.32K | 850.21K | 1.46M | 691.94K | 91.90K | 24.49K | -205.28K | -1.70M | -1.03M | 100.00K |
| EBITDA Ratio | 16.85% | 14.64% | 27.66% | 24.65% | 28.50% | 39.54% | 43.98% | 43.15% | 45.95% | 32.97% | 38.36% | 48.90% | 46.74% | 37.88% | 34.12% | 26.98% | 29.43% | 33.96% | 19.85% | 10.40% | 16.33% | 26.68% | 15.57% | 2.35% | 0.60% | -10.25% | -61.53% | -30.75% | 3.85% |
| Operating Income | 6.13M | 8.73M | 11.34M | 7.86M | 8.89M | 10.65M | 10.30M | 8.26M | 7.23M | 5.86M | 4.44M | 4.07M | 3.61M | 3.60M | 2.87M | 1.81M | 2.18M | 2.50M | 833.14K | 296.43K | 626.23K | 1.27M | 500.11K | -201.95K | -236.66K | -709.05K | -2.18M | -1.17M | 200.00K |
| Operating Income Ratio | 8.76% | 14.64% | 21.03% | 16.92% | 21.38% | 31.35% | 34.71% | 34.24% | 36.21% | 31.98% | 38.74% | 40.44% | 38.23% | 30.72% | 26.80% | 19.82% | 24.29% | 28.26% | 14.23% | 6.24% | 12.03% | 23.07% | 11.25% | -5.16% | -6.52% | -20.45% | -82.58% | -46.90% | 7.69% |
| Total Other Income/Expenses | 6.28M | 2.97M | 204.00K | -168.00K | 2.50M | -92.73K | -158.85K | -24.02K | 4.59K | -163.60K | 73.93K | 184.41K | 342.77K | 169.40K | 233.87K | 214.83K | 268.03K | 121.69K | 55.64K | 51.69K | 72.40K | -7.44K | -13.60K | -22.05K | -19.34K | 133.98K | 116.84K | -305.99K | 0.00 |
| Income Before Tax | 12.41M | 11.70M | 15.12M | 11.09M | 11.39M | 10.56M | 10.14M | 8.24M | 7.24M | 5.69M | 4.51M | 4.26M | 3.95M | 3.77M | 3.10M | 2.03M | 2.45M | 2.62M | 888.78K | 348.12K | 698.63K | 1.26M | 486.52K | -224.00K | -256.00K | -575.07K | -2.07M | -1.48M | 0.00 |
| Income Before Tax Ratio | 17.73% | 19.63% | 28.04% | 23.86% | 27.38% | 31.08% | 34.18% | 34.14% | 36.23% | 31.08% | 39.38% | 42.27% | 41.85% | 32.17% | 28.98% | 22.17% | 27.28% | 29.63% | 15.18% | 7.32% | 13.42% | 22.94% | 10.95% | -5.72% | -7.05% | -16.59% | -78.17% | -59.17% | 0.00% |
| Income Tax Expense | 2.46M | 1.73M | 2.63M | 1.30M | 2.05M | 1.97M | 1.20M | 2.45M | 2.29M | 1.85M | 1.49M | 1.37M | 1.14M | 1.06M | 948.43K | 614.58K | 720.61K | 1.16M | 212.90K | 85.80K | -137.86K | -1.25M | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | -38.80K | 0.00 |
| Net Income | 9.95M | 9.96M | 12.48M | 9.78M | 9.33M | 8.58M | 8.93M | 5.79M | 4.95M | 3.84M | 3.03M | 2.89M | 3.03M | 2.71M | 2.16M | 1.41M | 1.73M | 1.47M | 675.88K | 262.32K | 836.49K | 2.51M | 484.92K | -225.60K | -257.60K | -576.67K | -2.07M | -1.44M | 0.00 |
| Net Income Ratio | 14.22% | 16.72% | 23.16% | 21.05% | 22.44% | 25.27% | 30.12% | 23.98% | 24.79% | 20.98% | 26.40% | 28.66% | 32.05% | 23.16% | 20.13% | 15.44% | 19.24% | 16.55% | 11.54% | 5.52% | 16.07% | 45.69% | 10.91% | -5.76% | -7.10% | -16.63% | -78.23% | -57.62% | 0.00% |
| EPS | 0.50 | 0.50 | 0.62 | 0.49 | 0.52 | 0.49 | 0.52 | 0.34 | 0.29 | 0.23 | 0.19 | 0.18 | 0.19 | 0.17 | 0.14 | 0.09 | 0.11 | 0.10 | 0.05 | 0.02 | 0.06 | 0.18 | 0.04 | -0.02 | -0.02 | -0.04 | -0.62 | -0.49 | 0.00 |
| EPS Diluted | 0.49 | 0.49 | 0.60 | 0.47 | 0.50 | 0.48 | 0.50 | 0.33 | 0.29 | 0.23 | 0.18 | 0.18 | 0.19 | 0.17 | 0.13 | 0.08 | 0.10 | 0.08 | 0.04 | 0.02 | 0.05 | 0.17 | 0.03 | -0.02 | -0.02 | -0.04 | -0.62 | -0.49 | 0.00 |
| Weighted Avg Shares Out | 19.99M | 20.08M | 20.20M | 20.05M | 17.82M | 17.49M | 17.33M | 17.24M | 17.03M | 16.86M | 16.17M | 16.00M | 15.76M | 15.54M | 15.83M | 16.13M | 16.13M | 15.28M | 14.72M | 14.44M | 13.98M | 13.64M | 13.63M | 13.58M | 13.54M | 13.51M | 3.33M | 2.94M | 2.22M |
| Weighted Avg Shares Out (Dil) | 20.30M | 20.47M | 20.75M | 20.74M | 18.54M | 18.06M | 17.86M | 17.52M | 17.21M | 17.03M | 16.41M | 16.32M | 16.15M | 16.08M | 16.51M | 17.19M | 18.14M | 17.96M | 16.29M | 15.92M | 15.58M | 14.96M | 14.10M | 13.58M | 13.54M | 13.51M | 3.33M | 2.94M | 2.22M |
Simulations Plus Announces Third Quarter Fiscal Year 2024 Earnings and Conference Call Date
Simulations Plus (SLP) Upgraded to Buy: Here's Why
Simulations Plus (SLP) Buys Pro-ficiency Holdings for $100M
QHP Capital-Backed Pro-ficiency Acquired by Simulations Plus
Simulations Plus Acquires Pro-ficiency, Creating One-of-a-Kind Platform Spanning the Drug Development Continuum
Simulations Plus to Participate in 21st Annual Craig-Hallum Institutional Investor Conference
Simulations Plus (SLP) Launches GPX to Advance PBPK Modeling
Simulations Plus Releases GastroPlus® X, The Next Generation PBPK/PBBM Modeling & Simulation Software
New AI Bot Predicts These 7 Stocks Will Mint Millionaires
Simulations Plus (SLP) DILIsym Software Licenses Renewed by FDA
Source: https://incomestatements.info
Category: Stock Reports